The delivery of siRNA, via the use of their DDS with RGD (RpgWSC), for silencing the mRNA encoding the hBCL2 protein in a PC3 tumor xenograft mouse model, presented greater inhibition of tumor growth through the blocking of BCL2 protein expression, compared to a non-RGD modified delivery system (PgWSC) (Figure 2B). This evidence concerns the gene BCL2 and neoplasm.